Physician profile
John D Phillips
NPI 1770559403
$710.33
in general payments reported to CMS, 2019-2025
11 companies · $120 in 2025
The $120 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.41 · 2020: $40.40 · 2021: $290 · 2022: $117 · 2023: $43.17 · 2024: $83.30 · 2025: $120.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $246.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $233.47 | 2022-2025 | Clareon, Clareon Panoptix Pro, Hydrus Microstent |
| Abbvie INC. | $146.28 | 2021-2024 | |
| Allergan, INC. | $131.60 | 2021 | |
| Oyster Point Pharma, INC. | $48.38 | 2023-2024 | Tyrvaya |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $41.07 | 2020-2021 | |
| Johnson & Johnson Vision Care, INC. | $27.38 | 2022 | |
| Aerie Pharmaceuticals, INC. | $18.85 | 2020 | |
| Bausch & Lomb Americas INC. | $18.46 | 2024 | Miebo |
| Shire North American Group INC | $16.41 | 2019 | |
| Biotissue Holdings INC. | $15.43 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.